Published in J Urol on December 14, 2009
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int (2012) 1.87
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 1.80
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77
Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 1.75
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol (2008) 1.73
Outcomes following partial nephrectomy by tumor size. J Urol (2008) 1.72
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res (2005) 1.61
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60
Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol (2004) 1.58
The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol (2012) 1.58
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol (2011) 1.57
Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol (2012) 1.53
Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol (2012) 1.53
Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int (2014) 1.49
20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int (2012) 1.47
Robot-assisted partial nephrectomy: a large single-institutional experience. Urology (2010) 1.45
Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol (2010) 1.44
Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. J Urol (2013) 1.41
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int (2011) 1.31
The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol (2012) 1.19
Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer (2008) 1.16
Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology (2011) 1.11
A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int (2014) 1.06
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int (2009) 1.05
Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int (2013) 1.03
Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res (2013) 1.01
Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol (2011) 0.99
Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol (2011) 0.99
Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. Urology (2008) 0.99
The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int (2010) 0.97
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res (2009) 0.96
A case of incidental adrenocortical oncocytoma. Nat Clin Pract Urol (2006) 0.95
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors. J Urol (2012) 0.95
Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes. BJU Int (2012) 0.94
A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol (2013) 0.94
Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int (2008) 0.94
Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int (2005) 0.93
Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World J Urol (2012) 0.93
Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int (2011) 0.92
High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol (2012) 0.91
Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal gland is radiographically normal. J Urol (2011) 0.91
The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC). BJU Int (2014) 0.91
Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. Cancer (2012) 0.90
The relationship of postoperative complications with in-hospital outcomes and costs after renal surgery for kidney cancer. BJU Int (2012) 0.89
Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int (2012) 0.89
Carcinosarcoma of the prostate replacing the entire lower genitourinary tract. Urology (2009) 0.89
Hand-assisted laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. JSLS (2007) 0.87
Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol (2011) 0.86
Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol (2013) 0.86
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU Int (2009) 0.85
Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? BJU Int (2010) 0.85
A multidisciplinary evaluation of inter-reviewer agreement of the nephrometry score and the prediction of long-term outcomes. J Urol (2011) 0.85
Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res (2013) 0.84
Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU Int (2013) 0.84
Sperm cryopreservation and in vitro fertilization/intracytoplasmic sperm injection in men with congenital bilateral absence of the vas deferens: a success story. Fertil Steril (2004) 0.83
Paraneoplastic sarcoid-like reactions and the eye. Retina (2015) 0.82
Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol (2007) 0.82
Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. World J Urol (2014) 0.82
Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU Int (2011) 0.81
The androgen receptor and stem cell pathways in prostate and bladder cancers (review). Int J Oncol (2011) 0.81
Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol (2012) 0.80
The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. Urology (2013) 0.80
The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. J Urol (2013) 0.80
Gender-specific survival following radical cystectomy for pT4 bladder cancer. World J Urol (2013) 0.80
Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy. BJU Int (2014) 0.79
The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol (2012) 0.79
Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. Can J Urol (2010) 0.79
Iatrogenic splenectomy during nephrectomy for renal tumors. Int J Urol (2013) 0.79
Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. J Urol (2013) 0.79
Renal function outcomes in patients treated with partial nephrectomy versus percutaneous ablation for renal tumors in a solitary kidney. J Urol (2011) 0.78
ABLATE: a renal ablation planning algorithm. AJR Am J Roentgenol (2014) 0.78
Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy. Urol Oncol (2012) 0.78
Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis. J Urol (2012) 0.77
High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology (2015) 0.76
The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int (2009) 0.76
Treatment of the 2 to 3 cm renal mass. J Urol (2010) 0.76
Percutaneous renal cryoablation after partial nephrectomy: technical feasibility, complications and outcomes. J Urol (2012) 0.76
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int (2010) 0.75
Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology (2014) 0.75
Editorial comment. Urology (2011) 0.75
Editorial comment. J Urol (2010) 0.75
Postoperative intravesical therapy to prevent bladder tumor recurrence: are we ready to listen yet? Eur Urol (2011) 0.75
Trends in minimally invasive surgery for the kidney and prostate--when are you doing the patient a disservice by not referring? J Urol (2012) 0.75